Transforming concepts into clinical trials and creating a multisite network: The Leadership and Operations Center of the Antibacterial Resistance Leadership Group

Clinical Infectious Diseases

Volumn 64, Issue , 2017, Pages S8-S12

  Cross, Heather R ^a   Harris, Anthony ^b   Arias, Rebekka M ^a   Chambers, Henry F ^c   Fowler, Vance G ^a,d  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY   (United States)

Author keywords

Antibacterial Resistance; Clinical trial network; Infectious Disease; Mentoring

Indexed keywords

ACHIEVEMENT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL (TOPIC); FUTUROLOGY; INFECTION; LEADERSHIP; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; COMMUNICABLE DISEASE CONTROL; HUMAN; MANPOWER; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PERSONNEL; PROGRAM DEVELOPMENT; STANDARDS;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASE CONTROL; DRUG RESISTANCE, BACTERIAL; HUMANS; LEADERSHIP; PROGRAM DEVELOPMENT; RESEARCH PERSONNEL;

EID: 85033563161     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw825     Document Type: Article

References (16)

1. Chambers HF, Bartlett JG, Bonomo RA, et al. Antibacterial resistance leadership group: open for business. Clin Infect Dis 2014;58:1571-6.
2. Doernberg SB, Lodise T P, Thaden JT, et al. Gram-positive bacterial infections: research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S24-9.
3. Doi Y, Bonomo RA, Hooper DC, et al. Gram-negative bacterial infections: research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S24-9.
4. Talbot TR, Bratzler D W, Carrico RM, et al; Healthcare Infection Control Practices Advisory Committee. Public reporting of health care-associated surveillance data: recommendations from the Healthcare Infection Control Practices Advisory Committee. Ann Intern Med 2013;159:631-5.
5. Manca C, Hill C, Hujer AM, et al. Leading antibacterial laboratory research by integrating conventional and innovative approaches: the Laboratory Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S13-7.
6. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
7. Spellberg B, Guidos R, Gilbert D, et al; Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008;46:155-64.
8. van Duin D, Perez F, Rudin SD, et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother 2014;58:4035-41.
9. Anderson DJ, Jenkins T, Evans S, et al. The role of stewardship in antibiotic resistance: the Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S36-40.
10. National Center for Health Statistics. Health, United States, 2011: with special feature on socioeconomic status and health. 2012. Available at: http://www.cdc. gov/nchs/data/hus/hus11.pdf. Accessed 1 November 2016.
11. Cox E, Cavaleri M, Eichler HG, Woodcock J, Borio L. Facilitating antibacterial drug development in a time of great need. Clin Infect Dis 2016;63:S27-8.
12. Laughon MM, Benjamin DK Jr, Capparelli E V, et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol 2011;4:643-52.
13. Correa A, Del Campo R, Perenguez M, et al. Dissemination of high-risk clones of extensively drug-resistant Pseudomonas aeruginosa in Colombia. Antimicrob Agents Chemother 2015;59:2421-5.
14. Harris PN, Peleg AY, Iredell J, et al. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials 2015;16:24.
15. Banerjee R, Teng CB, Cunningham SA, et al. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis 2015;61:1071-80.
16. Tamma PD, Han JH, Rock C, et al; Antibacterial Resistance Leadership Group. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis 2015;60:1319-25.